Diarrhea News and Research

RSS
Diarrhea is loose, watery stools. A person with diarrhea typically passes stool more than three times a day. People with diarrhea may pass more than a quart of stool a day. Acute diarrhea is a common problem that usually lasts 1 or 2 days and goes away on its own without special treatment. Prolonged diarrhea persisting for more than 2 days may be a sign of a more serious problem and poses the risk of dehydration. Chronic diarrhea may be a feature of a chronic disease.

Diarrhea can cause dehydration, which means the body lacks enough fluid to function properly. Dehydration is particularly dangerous in children and older people, and it must be treated promptly to avoid serious health problems.
New 17-item questionnaire may help detect GI disorders in children with autism

New 17-item questionnaire may help detect GI disorders in children with autism

Study: Targeting specific genomic mutation in breast cancer improves survival

Study: Targeting specific genomic mutation in breast cancer improves survival

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma

Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

Newly discovered toxin stands out from others in the battle for microbial domination

Newly discovered toxin stands out from others in the battle for microbial domination

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

Study findings may explain sporadic outbreaks of C. difficile infections in hospitals

Study findings may explain sporadic outbreaks of C. difficile infections in hospitals

Novel 3-in-1 vaccine designed against traveler’s diarrhea

Novel 3-in-1 vaccine designed against traveler’s diarrhea